Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320487 · ClinicalTrials.gov registry record · Phase 2
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT02320487 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 102 participants.
The verdict
NCT02320487, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.
Interventions
- DRUG Obinutuzumab
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2019-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320487
The ClinicalTrials.gov registry entry for NCT02320487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT02320487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320487 about?
NCT02320487 is a clinical study titled "A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)". This is a Phase 2, open-label, multicenter study to evaluate the safety and efficacy of BG induction therapy in participants with previously untreated CLL. The anticipated time on study treatment is 24 weeks.
What is the current status of trial NCT02320487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2015-03-31. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT02320487?
The interventions under investigation include: Obinutuzumab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT02320487?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.